341 related articles for article (PubMed ID: 14607917)
21. Comparisons of DNA-mediated immunization procedures directed against surface glycoproteins of human immunodeficiency virus type-1 and hepatitis B virus.
Fomsgaard A; Nielsen HV; Nielsen C; Johansson K; Machuca R; Bruun L; Hansen J; Buus S
APMIS; 1998 Jun; 106(6):636-46. PubMed ID: 9725796
[TBL] [Abstract][Full Text] [Related]
22. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
Markiewicz MA; Fallarino F; Ashikari A; Gajewski TF
Int Immunol; 2001 May; 13(5):625-32. PubMed ID: 11312250
[TBL] [Abstract][Full Text] [Related]
23. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597
[TBL] [Abstract][Full Text] [Related]
24. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
25. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
27. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
28. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
29. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
30. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun.
Fensterle J; Grode L; Hess J; Kaufmann SH
J Immunol; 1999 Oct; 163(8):4510-8. PubMed ID: 10510394
[TBL] [Abstract][Full Text] [Related]
31. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
32. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
33. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
[TBL] [Abstract][Full Text] [Related]
34. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
35. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
36. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
Chiang EY; Stroynowski I
J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination.
Zöller M; Christ O
J Immunol; 2001 Mar; 166(5):3440-50. PubMed ID: 11207302
[TBL] [Abstract][Full Text] [Related]
39. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
Allen TM; Vogel TU; Fuller DH; Mothé BR; Steffen S; Boyson JE; Shipley T; Fuller J; Hanke T; Sette A; Altman JD; Moss B; McMichael AJ; Watkins DI
J Immunol; 2000 May; 164(9):4968-78. PubMed ID: 10779808
[TBL] [Abstract][Full Text] [Related]
40. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
Fallarino F; Ashikari A; Boon T; Gajewski TF
Int Immunol; 1997 Sep; 9(9):1259-69. PubMed ID: 9310829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
